文章：

代谢功能障碍相关脂肪性肝病与肝细胞癌的发展：发病机制与治疗挑战

MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges

原文发布日期：6 January 2024

DOI: 10.3390/cancers16020259

类型: Article

开放获取: 是

英文摘要：

Metabolic-dysfunction-associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease (NAFLD)) represents a rapidly increasing cause of chronic liver disease and hepatocellular carcinoma (HCC), mirroring increasing rates of obesity and metabolic syndrome in the Western world. MASLD-HCC can develop at an earlier stage of fibrosis compared to other causes of chronic liver disease, presenting challenges in how to risk-stratify patients to set up effective screening programmes. Therapeutic decision making for MASLD-HCC is also complicated by medical comorbidities and disease presentation at a later stage. The response to treatment, particularly immune checkpoint inhibitors, may vary by the aetiology of the disease, and, in the future, patient stratification will be key to optimizing the therapeutic pathways.

摘要翻译： 

代谢功能障碍相关脂肪性肝病（MASLD，既往称为非酒精性脂肪性肝病）已成为慢性肝病和肝细胞癌日益重要的致病因素，其发病率上升与西方世界肥胖及代谢综合征的增长趋势相呼应。相较于其他病因所致的慢性肝病，MASLD相关肝细胞癌可在肝纤维化更早期阶段发生，这对如何通过风险分层建立有效筛查体系提出了挑战。MASLD相关肝细胞癌的治疗决策亦因患者常合并多种内科疾病且确诊时多处于晚期而更趋复杂。针对不同治疗手段（特别是免疫检查点抑制剂）的疗效反应可能因疾病病因存在差异，未来通过患者分层优化治疗路径将成为关键策略。

原文链接：

MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges